

Structural ($\beta\alpha$)₈ TIM barrel model of 3-Hydroxy-3-methylglutaryl

Coenzyme A lyase.

Mutation of Ser⁷⁵, Ser²⁰¹ and Asp²⁰⁴ impairs the catalytic activity

Núria Casals¹, Paulino Gómez-Puertas², Juan Pié³, Cecilia Mir¹, Ramón Roca⁴,
Beatriz Puisac³, Rosa Aledo¹, Josep Clotet¹, Sebastián Menao³, Dolors Serra⁵,
Guillermina Asins⁵, Jacqueline Till⁶, Alun C. Elias-Jones⁷, Juan C. Cresto⁸,
Nestor A. Chamoles⁸, José E. Abdenur⁸, Ertan Mayatepek^{&9}, Guy Besley⁶,
Alfonso Valencia⁴ and Fausto G. Hegardt*⁵

¹ Unit of Biochemistry and Molecular Biology, International University of Catalonia, Sant Cugat del Vallés, Spain

² Bioinformatics Lab. (CAB-CSIC) Torrejón de Ardoz, Madrid, Spain

³ Department of Pharmacology and Physiology, University of Zaragoza, Zaragoza, Spain

⁴ Protein Design Group (CNB-CSIC), Cantoblanco, Madrid, Spain

⁵ Department of Biochemistry and Molecular Biology, School of Pharmacy, University of Barcelona, Barcelona, Spain,

⁶ Willink Biochemical Genetic Unit, Manchester, U.K.

⁷ Department of Pediatrics, Leicester General Hospital, Leicester, U.K.

⁸ Fundación para el Estudio de las Enfermedades Neurometabólicas, Buenos Aires, Argentina

⁹ Division of Metabolic and Endocrine Diseases, University Children's Hospital, Heidelberg, Germany

* To whom correspondence should be addressed:

Prof. Fausto G. Hegardt

Phone+34 93 402 4523

Department of Biochemistry

FAX +34 93 402 4520

School of Pharmacy

Email:hegardt@farmacia.far.ub.es

Avda. Diagonal 643,

E-08028 Barcelona, Spain

&Present Address: Department of General Pediatrics, University Children's
Hospital, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, D-40225
Düsseldorf, Germany

SUMMARY

The study describes three novel homozygous missense mutations (S75R, S201Y and D204N) in the 3-hydroxy-3-methylglutaryl-CoA lyase (HL) gene, which caused 3-hydroxy-3-methylglutaric aciduria in patients from Germany, England and Argentina. Expression studies in *E. coli* show that S75R and S201Y substitutions completely abolished the HMG-CoA lyase activity, while D204N reduced catalytic efficiency to 6.6 % of the wild type. We also propose a 3-D model for human HMG-CoA lyase containing a (beta-alpha)₈ (TIM) barrel structure. The model is supported by the similarity with analogous TIM barrel structures of functionally related proteins, by the localization of catalytic amino acids at the active site and by the coincidence between the shape of the substrate (3-hydroxy-3-methylglutaryl-CoA) and the predicted inner cavity. The three novel mutations explain the lack of HMG-CoA lyase activity on the basis of the proposed structure: in S75R and S201Y, because the new amino acid residues occlude the substrate cavity, and in D204N because the mutation alters the electrochemical environment of the active site. We also report the localization of all missense mutations reported to date and show that these mutations are located in the beta sheets around the substrate cavity.

INTRODUCTION

3-Hydroxy-3-methylglutaric aciduria (MIM246450) is a rare autosomal recessive metabolic disorder appearing in the first year of life. Acute episodes include vomiting, lethargy, hypotonia and apnea, sometimes evolving to coma (1, 2). Laboratory tests reveal metabolic acidosis with severe hypoketotic hypoglycemia on fasting or during acute illness, hyperammonemia and abnormal liver function tests. The disease is fatal in about 20 % of cases (3) although the symptoms are milder after childhood. Preliminary diagnosis is based on the excretory pattern of organic acids in urine, which include 3-hydroxy-3-methylglutaric, 3-hydroxyisovaleric, 3-methylglutaconic, 3-methylglutaric and 3-methylcrotonic acids (1, 4)

The origin of the disease is a mutation in the gene coding for 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) lyase (HL), which cleaves HMG-CoA to form acetyl-CoA and acetoacetate. This is the final step in the ketogenic pathway and leucine catabolism. The gene was assigned to the distal short arm of human chromosome 1p36.1 (5). It contains 9 exons and is transcribed in an mRNA of 1.7 Kb (6). The presence of the protein inside mitochondria and peroxisomes has been reported. The active site of HL has been shown to include the residues Cys 266 and His 233 (7, 8). To date, 38 probands have been diagnosed at the molecular level, and 22 different mutations of the HL gene have been reported (5, 6, 9-19). Only one of the missense mutations described, H233R, directly affects the catalytic residues. In contrast, there is no explanation for the effect of the other five reported missense mutations in the functional structure of the enzyme.

Here we report three novel homozygous missense mutations affecting patients from Germany, England and Argentina and describe the effect of these mutations in the protein activity by expression studies in *E. coli*. We also

propose a 3-D model for the human HMG-CoA lyase containing a (beta-alpha)₈ barrel structure, usually called TIM barrel, predicted by the relationship between *HMGL-like* and *hisA* (1qo2) family proteins. All the missense mutations reported to date are located in the proposed structural model around the catalytic cavity and their possible effects on enzyme activity are discussed.

MATERIAL AND METHODS

Case reports

Patient D.S. was a five-month-old Argentinean female born of healthy first-cousin parents after a normal pregnancy and delivery. On physical examination, the patient had all the clinical features of classical HMG-CoA lyase deficiency. The organic acids and acylcarnitine (3-hydroxyisovalerylcarnitine (2.42 mM) and methylglutaryl carnitine (0.09 mM)) found in blood and urine supported the diagnosis. She was given intravenous glucose and she recovered rapidly.

Comentario:

The first symptoms of the English proband (B.P.) appeared at 48 hours of age, and tests revealed metabolic acidosis (high pyruvate and lactate), hypoglycemia (1.2 mM) and 13.9 mM bicarbonate. The organic acids (3-hydroxyisovalerate, 3-methylglutarate, 3-methylglutaconate, glutarate, adipate and other dicarboxylic acids) found in blood and urine supported the diagnosis of 3-hydroxymethylglutaric aciduria. HMG-CoA lyase activity was 0.

Aciduria in the German patient (T.J) first appeared at 4 months of age after DPT/HiB/polio immunization, with recurrent vomiting, muscular hypotonia and comatose attacks. He showed hyperammonemia, liver dysfunction and massive excretion of organic acids typical of HMG-CoA lyase deficiency. Enzyme activity was $0.2 \text{ nmol} \cdot \text{min}^{-1} \cdot \text{mg}^{-1} \text{ protein}$. The boy recovered well with i.v. glucose and at 8 years shows no mental retardation, nor renal, hepatic or cardiac abnormalities.

Fibroblast culture and DNA isolation

A skin biopsy was taken from the patient B.P. Fibroblast explants were cultured in 25-cm² flasks in Dulbecco's Modified Eagle Medium (DMEM), 100

IU/ml of penicillin, and 100 mg/ml of streptomycin, 2 mM glutamine, 10% fetal calf serum, and 95% air-5% CO₂. Mutational analysis was performed in DNA isolated from leukocytes (D.S. and T.J.) or cultured fibroblasts (B.P.). DNA was isolated using the DNAzol® Reagent kit from Gibco BRL.

PCR amplification of genomic DNA

To amplify all exons, 200 ng of genomic DNA was amplified in a 100 µl mixture containing 0.2 mM of each dNTP, 25 pmol of each primer, 2.5 units of Taq DNA polymerase in 1 x PCR buffer and 2 mM MgCl₂ and the primers flanking intron sequences (11). The conditions were: 98 °C for 5 min, and subsequently 94 °C for 30 sec, 58 °C for 30 sec, 72°C for 30 sec for 35 cycles and finally 7 min at 72°C.

Missense mutation restriction analysis

Two specific primers: mut201, mut204 were designed to introduce an individual nucleotide mutation, which would generate a new restriction site *NcoI* or *DraII*, respectively, in the control DNA. The mutations S201Y (c602C>A) and D204N (c610G>A) abolished the restriction sites introduced by the primers mut201 and mut204, respectively. The mutation S75R (c225C>G) abolished an *AluI* site, present in the control DNA. Primers used in the amplifications are showed below. The modified nucleotide is underlined.

Mut201 sequence primer:

5'-GGGGTGCCACACCAATGGTGTCCCCCAATG-3'

Mut204 sequence primer:

5'-TGATCCCTGGGGTGCCACACCAATGGGG-3'

I3R1 sequence primer

5'-CCTATGTTCTCAACTTCTAC-3'

Genomic fragments amplified with primers F7E (18) and Mut201, with primers F7E and Mut204 or with primers F1 (15) and I3R1 in controls and

patients, were used as substrates for analytical digestion with *Nco* I, *Dra* II or *Alu* I respectively. Five units of restriction enzymes were added to 20µl of reaction medium. Digestions were incubated for 3 h at 37°C; the resulting restriction fragments were fractionated on a 4.5% metaphor agarose gel.

Construction of expression plasmids

HMG-CoA lyase cDNA was amplified by RT-PCR from 1 µg of total RNA isolated from control human fibroblasts, using Superscript II kit (Pharmacia) as described by the manufacturer. The region of the cDNA coding for the mature protein plus 5' Met and Gly codons was amplified with pfu DNA polymerase (Stratagene) and primers that introduced a *Nco*I site (5'-GCACCTCATCCATGGGCACT-3') and a *Bam*HI sites (5'-CCCAGGGATCCAGGTGGGC-3') at the ends of the amplified fragment. The 950-bp PCR fragment was cloned into *Nco*I/*Bam*HI-cut pTrc99A plasmid to give the expression plasmid pTr-HLwt. The insert was sequenced with Applied Biosystems 373 automated DNA sequencer to verify that no mutations had been introduced during PCR amplification.

Mutants S75R, S201Y and D204N of HL were constructed using the "Quick change" PCR-based mutagenesis procedure (Stratagene) with the pTr-HL-wt plasmid as a template. Primer 5'-TATAGAAACCACCAGGTTTGTGTCTCCTAAG-3' was used to construct pTr-HL-75R, primer 5'-GCTGCTACGAGATCTACCTGGGGGACACCATTG-3' was used to construct pTr-HL-201Y and primer 5'-GAGATCTCCCTGGGGAACACCATTGGTGTGG-3' was used to construct pTr-HL-204N. The appropriate substitutions and the absence of unwanted mutations were confirmed by sequencing the inserts.

Expression of HL in *E. coli*

Escherichia coli JM105 cells transformed with the expression plasmids were grown in LB broth supplemented with ampicillin (50 μ g/ml) at 25°C. When optical density reached DO₆₀₀= 0.6, expression of HL was induced by addition of IPTG to a final concentration of 1 mM. After 6 hours of induction, cells were recovered by centrifugation at 5,000 x g for 15 min at 4°C and frozen to -70°C until required for use.

Cell pellets were re-suspended in lysis buffer (NaCl 50 mM, Tris-HCl pH 7.5 5mM, DNase 10 μ g/ml, RNase 10 μ g/ml, PMSF 0.6 mM, Pepstatin 1 μ g/ml, Leupeptin 2 μ g/ml, Lysozyme 1 mg/ml) and incubated for 15 min at 4°C. Afterwards, the tubes were frozen to -70°C and thawed to 37°C. Soluble proteins were recovered by centrifugation at 10,000 x g for 10 min at 4°C and immediately frozen and stored at -70 °C. Protein quantification was performed using the Bio Rad protein assay with bovine albumin as standard.

HMG-CoA lyase activity

HMG-CoA lyase activity was measured by simple spectrophotometric method that determines the amount of acetoacetate produced (20). For HL specific activity determination, 2 μ g of soluble protein extracts and 800 nmols of substrate (HMG-CoA) were used. In the case of mutation extracts, determinations were also carried out with 20 or 75 μ g of soluble protein extract. The reaction assay was performed at 37°C for 15 min in a final volume of 250 μ l. One enzyme unit represents the formation of 1 μ mol of acetoacetate in 1 min. For Km determination 2 μ g of soluble crude extract was used. HMG-CoA concentrations ranged from 400 to 6,400 μ M. Results are given as mean values of at least four independent experiments.

Western blot analyses

A polyclonal rabbit antibody against residues 307-321 of human HL (which recognizes the C terminus of the enzyme) was raised by Sigma-Genosys. 50 µg of *E. coli* protein extract was subjected to SDS-PAGE electrophoresis. Electroblothing to nitrocellulose sheets was carried out for 2 h at 120 mA. Immunodetection of HL was performed using the antibody anti-HL (dilution 1/10.000) and the blots were developed with the ECL Western blotting system from Amersham Pharmacia Biotech.

Prediction of a structural model for HMGL_HUMAN.

The multiple sequence alignment used to provide the anchor points of the modeled human 3-hydroxy-3-methylglutaryl-CoA lyase (HMGL_HUMAN) to the template 3-D structure 1qo2 (*hisA*, (21)) was prepared by aligning the *HMGL_like* -PF00682- and *His_biosynth* -PF00977- Pfam database families (22). This alignment is similar to that obtained elsewhere (23) after four iterations of a PSI-Blast search of the NR protein sequence database from the NCBI, using the amino acid sequence of 1qo2 as seed (24).

To obtain a three-dimensional model of HMGL_HUMAN (amino acids 36-287), the program Swiss-Pdb Viewer and the SWISS-MODEL server facilities (25-28) (<http://www.expasy.ch/swissmod/SWISS-MODEL.html>) were used. The atomic coordinates of the (beta-alpha)₈ barrel template structure used to model the protein were obtained from the Protein Data Bank -PDB- (<http://www.rcsb.org/pdb>; entry 1qo2). The atomic coordinates of the 3-hydroxy-3-methylglutaryl-CoA molecule were obtained from the PDB entry 1qax. All missense mutants described in the study were modeled using the HMGL_HUMAN model as template.

The quality of the HMGL_HUMAN model was checked using the programs ProsaII (Center of Applied Molecular Engineering, Salzburg, Austria; (29), the WHAT-CHECK routines (30) from the WHAT IF program (31) and the PROCHECK validation program from the SWISS-MODEL server facilities

(32). The comparison of the values from the template structure 1qo2 *versus* the proposed HMGL_HUMAN model is accessible through the URL: http://www.cnb.uam.es/~pagomez/HM_Check.html. Briefly, the overall quality values of the model are poorer than the usual ones for experimental X-ray or NMR structures but acceptable in the expected region for protein structure models.

The interaction between HMG-CoA as the substrate and the proposed model was calculated using the macromolecular docking program “Hex” (33) based on spherical polar Fourier correlations. The picture of the surface, section and electrostatic potentials for the proposed protein models was produced using the GRASP program (34) and the ribbon plots were drawn with RASMOL (35).

RESULTS

Localization of the mutations responsible for 3-hydroxy-3-methylglutaric aciduria

DNA extracted from lymphocytes from either patients (D.S. and T.J.) or fibroblast cultures obtained from skin biopsies (B.P.) were used as templates for amplification by PCR of the nine exons of HMG-CoA lyase using primers described in (11). The size of the amplified fragments from the patients was identical to control. This suggested that point mutations in the HMG-CoA lyase gene were responsible for the disease. Sequencing of the amplified exons showed that patient T.J. had the new homozygous mutation S75R (c225C>G), patient B.P. had the new homozygous mutation S201Y (c602C>A), and patient D.S. had the new homozygous mutation D204N (c610G>A). The mutations localized by sequencing were corroborated by restriction analysis of PCR amplified fragments (Fig. 1).

Residues affected by mutation presented a high degree of conservation compared with HL from other species. Asp²⁰⁴ is invariant in the various HMG-CoA lyases from mammals (human, bovine, rat, mouse), chicken, plants (*Arabidopsis thaliana*, rice) and bacteria (*Pseudomonas mevalonii*, *Bacillus subtilis*, *Rhodospirillum rubrum*) for which primary structures have been

elucidated. Moreover, Asp²⁰⁴ is also invariant in 59 enzymes whose mechanism of reaction is analogous to HMG-CoA lyase, such as homocitrate synthase, 2-isopropyl malate synthase, oxoalate aldolase and pyruvate carboxylase from mammals, yeast, bacteria and archaea. Ser²⁰¹ is conserved in the HMG-CoA lyases of all organisms reported as well as Ser⁷⁵, which is conserved in all HMG-CoA lyases save those of *R. rubrum* and *P. mevalonii*, in which it is replaced by an alanine.

Expression of mutant proteins in *E. coli* and determination of enzymatic activity

The expression system used to overexpress mature wild-type and mutated HMG-CoA lyase was that described by Roberts et al. (36). *E. coli* JM105 cells were transformed with pTr-HL-wt, pTr-HL-75R, pTr-HL-201Y, pTr-HL-204N plasmids or the empty vector (pTr-0) and three different cell clones for each plasmid construct were induced to express HL. Expression levels were the same in the three clones of each construct and no expression was detected by Western blot in cells transfected with the empty vector (data not shown).

Specific HMG-CoA lyase activity from wild type and mutants was determined in the soluble fraction of crude extracts of transformed *E. coli*. Mutations S75R and S201Y completely abolished the enzyme activity, even when 75 µg of total protein extract was used in the assay. It was impossible to perform saturation kinetics and determine the *K_m* value for these mutants. The calculated *V_{max}* for the wild type was 9.5 U/mg protein and 1.35 U/mg for mutant D204N. The apparent *K_m* of the expressed protein was 3.1 mM for the wild type and 6.6 mM for the mutant D204N. Therefore, the mutant decreased *V_{max}* 7.1 fold and increased the *K_m* 2.1 fold with respect to the wild type (Fig 2). The catalytic efficiency (*V_{max}/K_m*) for the mutated enzyme was 6.6 % of the wild type, which confirmed the aciduria observed in the patient.

Structural model of human HMG-CoA lyase

A relation was previously found between the 3-hydroxy-3-methylglutaryl-CoA lyase (*HMGL*)-like family of proteins (22) and the TIM-barrel *hisA* gene from *Thermotoga maritima* (Protein Data Bank -PDB- entry 1qo2 (21), which suggested that a (beta-alpha)₈ barrel structure (also known as TIM barrel) could be adopted by the *HMGL*-like family (23). This type of structure consists of an eight fold repetition of a beta sheet-loop-alpha helix-loop motif, with the beta sheets forming the inner face of the barrel and the alpha helices on the external face. In addition, using methods based on recursive intermediate sequence searching (37) as well as the hierarchical classification of proteins contained in the PROTOMAP database (38), a further relationship was found between HMG-CoA lyase and the *hisA* (1qo2) protein families. On the basis of all these results, multiple alignment of both protein families was performed (Fig. 3) and the information extracted was used to construct a 3-D model of the human HMG-CoA lyase, using the structure of *T. maritima* HisA protein as a template (Fig. 4). This model is a (beta-alpha)₈ barrel with short loops at the NH₂-terminal face, and long and probably non-structured loops at the C-terminal face. The secondary structure prediction for the eight beta sheets and alpha helices of the HMG-CoA lyase sequences calculated using the PHD method (39,40) is compatible with the alignment made using sequence searching methodologies, showing a high correlation between structural and sequence alignments.

In the proposed model for human HMG-CoA lyase the side chains of the barrel forming beta sheets conform a central cavity, which is similar to the structure of other TIM barrel-like enzymes such as methylmalonyl-CoA mutase (PDB entry 7req) (41). A section of the proposed model (Fig. 4C, right panel) shows the contour of the central cavity where the calculations from the macromolecular docking program “Hex” localized the substrate, suggesting that 3-hydroxy-3-methylglutaryl-CoA crosses the cavity and locates the small 3-

hydroxy-3-methylglutaryl head close to the His233-defined active site. The location of the active enzyme locus in the COOH-face of the beta barrel is consistent with the general disposition of the active sites in the TIM barrel-like structures (42).

Once the 3D-model for human HL was established, residues affected by the three novel mutations here described (Ser⁷⁵, Ser²⁰¹ and Asp²⁰⁴) and by all missense mutations previously reported (Arg⁴¹, Asp⁴², Val⁷⁰, His²³³, Leu²⁶³ and Glu²⁷⁹) (13, 10, 8, 18, 9) were localized in the model. Interestingly, all the mutated residues (marked as red dots in Figs. 3 and 4) except Glu²⁷⁹ are localized in the beta sheets and form part of the central cavity, where the HMG-CoA substrate is assumed to be accommodated.

When Val⁷⁰, Ser⁷⁵ and Ser²⁰¹ are replaced by Leu⁷⁰, Arg⁷⁵ and Tyr²⁰¹, the proposed substrate cavity is occluded by the longer side chain of the mutated amino acids and the entrance of the substrate is prevented (Fig 5), which is consistent with the complete absence of activity observed in expression studies performed with mutants S75R and S201Y.

Some of the residues that can be mapped with confidence are those previously defined as essential to the enzyme activity on the basis of mutational studies. His²³³, reported as the main amino acid responsible for HMG-CoA lyase catalysis, is located on beta sheet 7, beside the substrate cavity (Figs. 3 and 4B). Kinetic analysis with site-directed mutants H233R and H233A showed a decrease in activity of four orders of magnitude (8), without modification of the *K_m*. In the model, the catalytic His²³³ is located exactly at the site in which the 3-hydroxy-3-methylglutaryl group is connected with the CoA, thus validating the model. His²³⁵ (suggested to have an important function on cation binding) is located at 5.3 Angstroms from His²³³, which could explain the effect of site-directed mutants (H235A and H235D) on catalytic activity (1/15 with respect to wild type) and substrate affinity (*K_m* was increased 4 fold) (43).

Since Asp²⁰⁴ is close to His²³³ (less than 4 Angstroms) in the model (Fig. 4B), we propose that the third novel mutation here described, D204N, could affect the activity of the enzyme by changing the polarity of the active center, which fits with the decreased *V_{max}* observed in the expressed protein.

In addition, Arg⁴¹ and Asp⁴², which are on the first beta sheet (Fig. 3), are close to the catalytic residue His²³³ (Fig. 4). Mutations in these amino acid residues R41Q, D42H, D42G, responsible for 3-hydroxy-3-methylglutaric aciduria in some patients (13), produce changes of charge, which may also affect the efficiency of catalysis. On the other hand, Leu²⁶³ located close to beta sheet 8, surrounds the cavity and is three amino acids away from Cys²⁶⁶, which is considered to be the residue to which the acetoacetic group binds before leaving the enzyme after catalysis (7). Mutation L263P (18) may interfere with the positioning of the acetoacetic group before leaving the enzyme. Mutation E279K (9) is at the beginning of alpha helix 8 (Fig 3) and the model cannot directly explain the absence of enzyme activity in this mutated enzyme, since it is located outside the inner cavity (Fig 4). Since some proteins that fold as TIM barrels utilize loop movements to close the active site once the substrate is bound (44), mutation E279K may block this effect in catalysis.

DISCUSSION

Mutational studies in patients suffering from 3-hydroxy-3-methyl glutaric aciduria permit the detection of residues that are important for HL activity. The three novel mutations described here dramatically reduce the catalytic efficiency of the enzyme as demonstrated by expression studies in *E. coli*. S75R and S201Y completely abolished the enzyme activity while D204N, very close to S201Y, reduced catalytic efficiency to 6.6 % of the wild type. However, these studies do not indicate how these mutations produce the enzyme disfunction. So, we built a structural model of the enzyme that could explain the effect of each mutation on the enzyme structure and predict the effect of the new mutations.

Enzymes containing the (beta-alpha)₈ barrel structural fold account for up to 10% of all the enzymes of the central metabolism pathways and support a wide variety of functions (42). The amino acids conforming the active locus are

generally located at the COOH-terminal ends of the beta sheets and at the loops that connect the beta sheets to the alpha helices (42). Copley and Bork (23), using the Psi-Blast sequence-based search method (24), provided compelling evidence that most of the known and predicted TIM barrels found in central metabolism share not only a structural fold but also a common evolutionary origin. These authors also found related sequences in enzymes of central metabolism whose 3-D structure has not yet been solved, although it could be TIM barrel-like folds on the basis of sequence similarity. A relation was found between members of the Pfam *HMGL-like* (22) family of proteins and the TIM-barrel *hisA* gene from *T. maritima* (Protein Data Bank -PDB- entry 1qo2 (21), leading to the suggestion that a $(\beta\text{-}\alpha)_8$ barrel structure could be adopted by the *HMGL-like* family.

Two other independent approaches supported a direct sequence relationship between the human HMG-CoA lyase and the *hisA* (1qo2) respective protein families. First, a program based on recursive intermediate sequence search methodology (37), confirmed a relation between those two families through a third family in the Pfam *trp_syntA* profile. In linking (or intermediate search) methods (45-48) two proteins are considered to be related either if their similarity score is above a certain cutoff or if there is a third protein related to both above a cutoff, following a transitive principle. Further evidence of sequence relation can be found at the PROTOMAP site (<http://www.protomap.cs.huji.ac.il>), which offers a hierarchical classification of the Swissprot proteins into clusters of related proteins (38). The relation described in PROTOMAP links at a lower reliability level "1e-0" the clusters 257 (HMGL proteins and related) and 503 (HisA proteins and related) through the small cluster 2889, related in addition to the cluster 163 (*trp_synt* proteins and related). On the basis of these sequence relations we suggest an alignment combining the Pfam *HMGL_like* and *His_biosynth* families of proteins (Fig. 3). In turn, this alignment was used to construct a 3-D model of the human HMG-

CoA lyase, using the structure of the *T. maritima* HisA protein (PDB entry 1qo2) as template.

The proposed structural model for HMG-CoA lyase corresponds to a (beta-alpha)₈ barrel (Fig. 4) with short loops on the NH₂-terminal face and, in contrast, long and probably non-structured loops on the COOH-terminal face of the beta barrel. The model is not accurate enough to infer the precise location of all amino acids, since major movements of backbone and side-chains are expected (49). However, it is sufficient to provide a suitable framework to determine the general shape, the arrangement of the structural elements and the localization of key residues. In the case of *T. maritima* HisA protein (PDB entry 1qo2), the average in RMS deviation, as deduced from the data present in the FSSP (Fold classification based on Structure-Structure alignment of proteins) database is less than 3.5 angstroms for TIM barrels with values of number of aligned residues and percent identity in the same range as the ones between HMG-CoA lyase and HisA protein (227 residues and 9% respectively) (50).

Nine missense mutations producing 3-hydroxy-3-methylglutaric aciduria have been described so far in the HMG-CoA lyase gene. Some of the residues that can be mapped with confidence in the model have been previously defined as essential to the enzyme activity based on mutational studies: His²³³ (8,18), which is considered as the active site, Arg⁴¹ and Asp⁴² (13). In the present model, all these amino acids, as well as Leu²⁶³ (18) and Asp²⁰⁴ (this paper), are located on the COOH-terminal face of the barrel forming beta sheets 1, 6, 7 and 8. All surround the end of a central cavity that runs through the entire protein structure (Fig. 4, lower panel), probably forming part of an active locus, where the head of HMG-CoA fits to be split off. The location of all these functionally essential residues in the COOH-face of the beta barrel is consistent with the general arrangement of the active sites in the TIM barrel-like structures (42). Since they are all close to His²³³ in the modeled structure, these mutations could affect the activity of the enzyme by changing the appropriate environmental

requirements of the active center. The kinetic behavior of D204N expressed protein is in accordance with the model: the catalytic efficiency is decreased 15.1 fold (6.6 %) respect with the wild-type while the substrate affinity is barely modified (the apparent K_m only doubles in D204N respect to the wild-type). The loss of enzyme activity of the mutants S75R and S201Y (this paper) and of V70L (10), has an alternative explanation within the proposed model. In the mutant proteins the side chains of the Arg⁷⁵ and of Tyr²⁰¹ are much larger than those of Ser⁷⁵ and Ser²⁰¹ (wild type) and may occlude the proposed cavity, preventing the entrance of the substrate (Fig. 5B). These changes may explain the lack of enzyme activity.

These results indicated that in HL not only the amino acids that participate directly in the catalytic reaction (Cys²⁶⁶ and His²³³), but probably all the amino acids surrounding the substrate cavity are critical for enzyme activity. Although Glu²⁷⁹ is outside the central cavity (it is in alpha helix 8), it may play a putative role in catalysis by utilizing loop movements to close the active site once substrate is bound, as has been shown in some enzymes that fold as TIM barrels (44). This would correlate with the finding that patient having mutation E279K did not develop lethal symptoms (onset of the disease was at 7 months, residual HMG-CoA lyase activity was 2% of the wild type and patient development at 4.4 years is normal) (9), and the involvement of Glu²⁷⁹ in catalysis in this patient could be only partially impeded by the E279K substitution.

Other possible speculations on the role of specific residues previously identified as important for the enzyme activity, such as His²³⁵ (43) or Cys²⁶⁶ (7) can be based on their location in the structural model. Thus, His²³⁵ is located at a relatively short distance from the substrate (5.3 angstroms), which could explain the effect of mutants H235A and H235D in both catalytic activity (1/15 with respect to wild type) and substrate affinity (K_m was increased 4 fold) (50). Cys²⁶⁶, which localize in the COOH-terminal loop between beta strand eight and alpha helix eight, could take part in enzyme function through putative loop

movements, as supposed for Glu²⁷⁹. Although these structural arrangements could explain the lack of activity of the HMGL_HUMAN mutants described, these structural data should be considered with caution, as they are derived from a low-resolution homology-based model.

Expression studies to identify the crystallographic structure of the HL protein are being carried out in our laboratory, in order to corroborate the model and improve the precision with which the aminoacids are localized.

ACKNOWLEDGMENTS

This study was supported by Grants PB95-0012 from the Direcció General de Investigació Científica y Tècnica, from the Fundació de la Marató de TV3 (Barcelona), G03/054 of the Spanish Ministry of Health and 2001SGR0123 from the Generalitat de Catalunya, Spain (given to F.G.H.), Grant CICYT 2002-2003 given to A.V., Grant from the Ramon Areces Foundation given to P. G-P and Grant P100/99-BM from the Diputació General de Aragón (given to J.P.). C.M. and B.P. are the recipients of fellowships from the Universitat Internacional de Catalunya and from the Diputació General de Aragón, respectively. The editorial help of Robin Rycroft is gratefully acknowledged.

REFERENCES

1. Wysocki, S.J., and Hahnel, R. (1986) *J. Inherit. Metab. Dis.* **9**, 225-233.
2. Gibson, K.M., Breuer, J., Kaiser, K., Nyhan, W.L., McCoy, E.E., Ferreira, P. Greene, C.L., Blitzer, M.G., Shapira, E., Reverte, F., Conde, C., Bagnell, P., and Cole, D.E.C. (1988) *J. Inherit. Metab. Dis.* **11**, 76-87.
3. Sweetman, L., and William, J.C. (1995) In *The Metabolic and molecular basis of inherited disease* (Schreiver C.R., A.L. Beaudet, W.S. Sly, W.S. and Valle, D. Editors). Vol I, 7th Ed., Mc Graw-Hill, New York, N.Y. 1400-1402.
4. Faull, K.F., Bolton, P.D., Halpern, B., Hammond, J., and Danks, D.M. (1976) *Clin. Chim. Acta* **73**, 553-559.
5. Wang, S.P., Nadeau, J.H., Duncan, A., Robert, M.F., Fontaine, G., Schappert, K., Johson, K.R., Zietkiewicz, E., Hruz, P., Mizioroko, H., and Mitchell, G.A. (1993) *Mamm. Genome* **4**, 382-387.
6. Mitchell, G.A., Robert, M.F., Hruz, P.W., Wang, S., Fontaine, G., Behnke, C.E., Mende-Mueller, L.M., Schappert, K., Lee, C., Gibson, K.M., and Mizioroko, H.M. (1993) *J. Biol. Chem.* **268**, 4376-4381.
7. Roberts, JR., Narasimhan, C., and Mizioroko, H.M. (1995) *J. Biol. Chem.* **270**, 17311-17316.
8. Roberts, J.R., Mitchell, G.A., and Mizioroko, H. (1996) *J. Biol. Chem.* **271**, 24604-24609
9. Muroi, J., Yorifuji, T., Uematsu, A., Shigematsu, Y., Onigata, K., Maruyama, H., Nobutoki, T., Kitamura, A., and Nakahata, T. (2000). *Hum. Genet.* **107**, 320-326.
10. Mitchell, G.A., Robert, M.F., Fontaine, G., Wang, S., Lambert, M., Cole, D., Lee, C., Gibson, K.M., and Mizioroko, H. (1992) *Am. J. Hum. Genet.* **51** (suppl.):A173
11. Wang S.P., Robert M.F., Gibson K.M., Wanders R.J.A., and Mitchell G.A. (1996) *Genomics* **33**, 99-104.

12. Mitchell, G.A., Jakobs, C., Gibson, K.M., Robert, M.F., Burlina, A., Dionisi-Vici, C., and Dallaire, L. (1995) *Prenat. Diagn.* **15**, 725-729.
13. Mitchell, G.A., Ozand, P.T., Robert, M.-F., Ashmarina, L., Roberts, J., Gibson, K.M., Wanders, R.J., Wang, S., Chevalier, I., Plöchl, E., and Mizioro, H. (1998) *Am. J. Hum. Genet.* **62**, 295-300.
14. Buesa, C., Pié, J., Barceló, A., Casals, N., Mascaró, C., Casale, C.H., Haro, D., Duran, M., Smeitink, J. A. M., and Hegardt, F. G. (1996). *J. Lipid Res.* **37**, 2420-2432
15. Pié, J., Casals, N., Casale, C. H., Buesa, C., Mascaró, C., Barceló, A., Rolland, M. O., Zabet, T., Haro, D., Eyskens, F., Divry, P., and Hegardt, F. G. (1997). *Biochem. J.* **323**, 329-335
16. Casals, N., Pié, J., Casale, C. H., Zapater, N., Ribes, A., Castro-Gago, M., Rodriguez-Segade, S., Wanders, R. J. A., and Hegardt, F. G. (1997) *J. Lipid Res.* **38**, 2303-2313.
17. Casale, C. H., Casals, N., Pié, J., Zapater, N., Pérez-Cerdá, C., Merinero, B., Martínez-Pardo, M., García-Peñas, J. J., García-Gonzalez, J. M., Lama, R., Poll-The, B.-T., Smeitink, J. A. M., Wanders, R. J. A., Ugarte, M., and Hegardt, F. G. (1998) *Arch. Biochem. Biophys.* **349**, 129-137.
18. Zapater, N., Pié, J., Lloberas, J., Rolland, M.O., Leroux, B., Vidailhet, M., Divry, P., Hegardt, F.G., and Casals, N. (1998). *Arch. Biochem. Biophys.* **358**, 197-203.
19. Funghini, S., Pasquini, E., Cappellini, M., Donati, M.A., Morrone, A., Fonda, C., and Zammarchi, E. (2001) *Mol. Genet. Metab.* **73**, 268-275.
20. Wanders, R.J.A., Schutgens R.B.H., and Zoeters, P.H.M. (1988). *Clin. Chim. Acta* **171**, 95-101.
21. Lang, D., Thoma, R., Henn-Sax, M., Sterner, R., and Wilmanns, M. (2000) *Science* **289**, 1546-1550.
22. Bateman, A., Birney, B., Durbin, R., Eddy, S.R., Howe, K.L., and Sonnhammer, E.L. (2000) *Nucl. Acids Res.* **28**, 263-266.

23. Copley, R.R., and Bork, P. (2000) *J. Mol. Biol.* **303**, 627-640.
24. Altschul, S.F., Madden, T.L., Schäffer, A.A., Zhang, J., Zhang, Z., Miller, W., and Lipman, D.J. (1997) *Nucleic Acids Res.* **25**, 3389-3402.
25. Guex, N., and Peitsch, M.C. (1997) *Electrophoresis* **18**, 2714-2723
26. Guex, N., Diemand, A., and Peitsch, M.C. (1999) *Trends Biochem. Sci.* **24**, 364-367.
27. Peitsch, M.C. (1995) *Bio/Technology* **13**, 658-660.
28. Peitsch, M. C. (1996) *Biochem. Soc. Trans.* **24**, 274-279.
29. Sippl, M.J. (1993) *Proteins* **17**, 355-362.
30. Hooft, R.W.W., Vriend, G., Sander, C., and Abola, E.E. (1996) *Nature* **381**, 272.
31. Vriend, G. (1990) *J. Mol. Graph.* **8**, 52-56.
32. Laskowski R. A., MacArthur, M. W., Moss, D. S., and Thornton, J. M. (1993) *J. Appl. Cryst.* **26**, 283-291.
33. Ritchie, D.W., and Kemp, G.J. (2000) *Proteins* **39**, 178-194
34. Nicholls, A., Bharadwaj, R., and Honig, B. (1993) *Biophys. J.* **64**, A166.
35. Sayle, R.A., and Milner-White, E.J. (1995) *Trends Biochem. Sci.* **20**, 374.
36. Roberts, J.R., Narasimhan, C., Hruz, P.W., Mitchell, G.A., and Mizioro, H.M. (1994) 3-hydroxy-3-methylglutaryl-CoA lyase: *J. Biol. Chem.* **269**, 17841-17846.
37. Abascal, F., and Valencia, A. (2003) *Proteins In the Press*
38. Yona, G., Linial N., Tishby, N., and Linial, M. (1998). Proc. Int. Conf. Intell. Syst. Mol. Biol. pp. 212-221 (<http://www.protomap.cs.huji.ac.il>).
39. Rost, B., and Sander, C. (1993) *J. Mol. Biol.* **232**, 584-599
40. Rost, B., and Sander, C. (1994) *Proteins* **19**, 55-72
41. Mancia, F., Smith, G.A., and Evans, P.R. (1999) *Biochemistry* **38**, 7999-8005.
42. Gertl, J.A. (2000) *Nature Struct. Biol.* **7**, 171-173.
43. Roberts, J.R., and Mizioro, H.M. (1997) *Biochemistry* **36**, 7594-7600
44. Miller, B.G., Hassell, A.M., Wolfenden, R., Milburn, M.V., and Short, S.A. (2000) *Proc. Natl. Acad. Sci. USA* **97**, 2011-2016

45. Holm, L., and Sander, C. (1997) *Proteins* **28**, 72-82.
46. Abagyan, R.A., and Batalov, S. (1997) *J. Mol. Biol.* **273**, 355-368.
47. Park J., Teichmann S. A., Hubbard T., and Chothia C. (1997) *J. Mol. Biol.* **273**, 349-354.
48. Salamov A. A., Suwa M., Orengo C. A., and Swindells M. B. (1999) *Protein Eng.* **12**, 95-100.
49. Chothia, C., and Lesk, A.M. (1986) *EMBO J.* **5**, 823-826
50. Holm, L., and Sander, C. (1996). *Science* **273**, 595-603.

LEGENDS TO THE FIGURES

Fig. 1

Restriction enzyme analysis of mutations S75R, S201Y and D204N

A. Patient BP and control genomic DNA amplified fragments using F8/Mut201 primers were incubated with *Nco* I. Two fragments of 88 bp and 30 bp (lane 3) in the control and only one fragment of 115 bp (lane 4) in the patient are observed. Lanes 1 and 2 are amplified fragments of control and patient without digestion. **B.** Patient DS and control genomic DNA amplified fragments using F8/Mut204 primers were incubated with *Dra* II. Two fragments of 90 bp and 30 bp in the control DNA (lane 3), and only one fragment of 120bp (lane 4) in the patient are observed. Lanes 1 and 2 are amplified fragments of control and patient without digestion. **C.** Patient JT and control genomic DNA amplified fragments using F1/I3R1 primers were incubated with *Alu* I. Two fragments of 117 bp and 47 bp in the control (lane 3) and only one fragment of 164bp in the patient (lane 4) are observed. Lanes 1 and 2 are amplified fragments of control and patient without digestion. Mk, molecular weight markers.

Fig. 2

Saturation kinetics of wild-type and D204N mutant HL expressed in *E. coli*.

2 µg of crude extracts from *E.coli* expressing wild-type (circles) or D204N HL (squares) protein were assayed for HL activity with different concentrations of HMG-CoA

Fig. 3.

Multiple sequence alignment of representative proteins of the *HMGL_like* and *His_biosynth* families.

The amino acid sequence and the secondary structure of the PDB structure 1qo2A included in the alignment were both derived from the FSSP database (48). The protein family definition corresponds to the Pfam database (22). Residues are colored by average BLOSUM62 substitution matrix score using the Belvu v.2.8 program (Erik Sonnhammer, <http://www.sanger.ac.uk/~esr/Belvu.html>). The location of the beta strands and alpha helices of the central eight-fold (beta-alpha) barrel of the proposed model for HMGL_HUMAN are indicated (E: beta strand; H: alpha helix) and numbered from 1 to 8. The positions of the HMGL_HUMAN amino acids R41, D42, V70, S75, S201, D204, H233, L263 and E279 are marked as asterisks.

Fig. 4

Ribbon plot and solvent-accessible surface representations of the proposed model of HMGL_HUMAN.

A. View from the NH₂-terminal face of the central beta barrel. Left: the beta strands of the central barrel are in orange, the alpha helices are in yellow and they are numbered as in Fig. 3. The loops at the COOH- and the NH₂-terminal faces are colored in green and blue respectively; the secondary structure elements of the loops are not shown. The positions of the NH₂- and COOH-termini are indicated. The HMGL_HUMAN amino acids R41, D42, V70, S75, S201, D204, H233, L263 and E279 are represented as red spheres. Right: the

electrostatic potential [-15 (red) to +15 kT (blue)] has been plotted on to the model surface and the approximate position of some residues are shown. **B.** View from the COOH-terminal face of the central beta barrel, symbols are as in A. **C.** Left: side view of the ribbon plot representation of the model; symbols are as in A. Right: slice section of the model surface representation along the putative substrate cavity. The approximate positions of the HMGL_HUMAN D204 and H233 residues are indicated. A solvent-accessible surface and "ball-and-stick" representations of 3-hydroxy-3-methylglutaryl-CoA have been included.

Fig 5

A. Ser201Tyr mutant. Left: slice section of the model surface representation along the putative substrate cavity. The approximate positions of the HMGL_HUMAN D204 and H233 residues are indicated. The atoms of S201 are represented as purple spheres. A "ball-and-stick" representation of a 3-hydroxy-3-methylglutaryl-CoA molecule has been inserted into the model putative substrate cavity solely to illustrate the proposed substrate-enzyme structural interaction. Right: slice section of the mutant Ser201Tyr surface model showing the occlusion of the putative substrate cavity. The atoms of the Y201 amino acid are represented as purple spheres. **B. Ser75Arg mutant.** Left: slice section of the model along the putative substrate cavity. The view of this section is approximately the opposite of that shown in A. The atoms of S75 are represented as green spheres. Right: slice section of the mutant Ser75Arg showing the location of the R75 atoms (green spheres) occluding the substrate cavity. **C. Val70Leu mutant.** Details of the NH₂- terminal face of the wild-type protein surface model (left) and the Val70Leu mutant (right). The orange area occluding the end of the cavity (right) represents the surface of the Leu⁷⁰ side group.




Figure 1




Figure 2

```

HMG1_HUMAN    H1      **      HHHHHHHHHH          HHHHHH          HHHH
36  VMGFPRDS     ..LQNEKNI VSPYVKIKLIDIMSESEELQSVIHTUSVSPKVVVPOMGDHHEVILKQK...F
HMG1_MOUSE    H2      **      HHHHHHHHHH          HHHHHH          HHHH
36  VMGFPRDS     ..LQNEKSI VTPYVKIKLIDIMSESEELQSVIHTUSVSPKVVVPOMADHSDVILKQK...F
HMG1_RAT       H3      * E2 *          EEEEE                    HHHH
36  VMGFPRDS     ..LQNEKSI VTPYVKIKLIDIMSESEELQSVIHTUSVSPKVVVPOMADHSDVILKQK...F
HMG1_CHICK     H4      * E2 *          EEEEE                    HHHH
9   VMGFPRDS     ..LQNEKSI VTPYVKIKLIDIMSESEELQSVIHTUSVSPKVVVPOMADHSDVILKQK...F
HMG1_PSENV     H5      * E2 *          EEEEE                    HHHH
7   VMGFPRDS     ..LQNEKSP LSVAAKLVGELIGLQGLSHIISGAEVSEERVWVFMAGSDEVILKQF...S..N
HMG1_MOUSE    H6      * E2 *          EEEEE                    HHHH
10  CDATFAS     ..LQNEKSI VTPYVKIKLIDIMSESEELQSVIHTUSVSPKVVVPOMADHSDVILKQF...S..N
N1FV_RHOCA    H7      * E2 *          EEEEE                    HHHH
PYCB_METUA    H8      * E2 *          EEEEE                    HHHH
H1S4_MYCTU    H9      * E2 *          EEEEE                    HHHH
H1S4_STRCO    H10     * E2 *          EEEEE                    HHHH
H1S4_ECOLI    H11     * E2 *          EEEEE                    HHHH
H1S4_HAEIN    H12     * E2 *          EEEEE                    HHHH
19Q2A_HAEIN   H13     * E2 *          EEEEE                    HHHH
19Q2A_SF      H14     * E2 *          EEEEE                    HHHH

HMG1_HUMAN    H1      **      HHHHHHHHHH          HHHHHH          HHHH
96  EGTVLPTLNK   ..LQNEKSI VTPYVKIKLIDIMSESEELQSVIHTUSVSPKVVVPOMADHSDVILKQK...F
HMG1_MOUSE    H2      **      HHHHHHHHHH          HHHHHH          HHHH
96  EGTVLPTLNK   ..LQNEKSI VTPYVKIKLIDIMSESEELQSVIHTUSVSPKVVVPOMADHSDVILKQK...F
HMG1_RAT       H3      * E2 *          EEEEE                    HHHH
99  EGTVLPTLNK   ..LQNEKSI VTPYVKIKLIDIMSESEELQSVIHTUSVSPKVVVPOMADHSDVILKQK...F
HMG1_CHICK     H4      * E2 *          EEEEE                    HHHH
70  DGVSYVLPN   ..LQNEKSI VTPYVKIKLIDIMSESEELQSVIHTUSVSPKVVVPOMADHSDVILKQK...F
HMG1_PSENV     H5      * E2 *          EEEEE                    HHHH
72  DGVSYVLPN   ..LQNEKSI VTPYVKIKLIDIMSESEELQSVIHTUSVSPKVVVPOMADHSDVILKQK...F
LEU1_LACLA    H6      * E2 *          EEEEE                    HHHH
76  TALARCVR    ..LQNEKSI VTPYVKIKLIDIMSESEELQSVIHTUSVSPKVVVPOMADHSDVILKQK...F
N1FV_RHOCA    H7      * E2 *          EEEEE                    HHHH
72  PVVNCILR    ..LQNEKSI VTPYVKIKLIDIMSESEELQSVIHTUSVSPKVVVPOMADHSDVILKQK...F
N1FV_RHOCA    H8      * E2 *          EEEEE                    HHHH
72  DVQVLSGIR   ..LQNEKSI VTPYVKIKLIDIMSESEELQSVIHTUSVSPKVVVPOMADHSDVILKQK...F
H1S4_MYCTU    H9      * E2 *          EEEEE                    HHHH
H1S4_STRCO    H10     * E2 *          EEEEE                    HHHH
H1S4_ECOLI    H11     * E2 *          EEEEE                    HHHH
H1S4_HAEIN    H12     * E2 *          EEEEE                    HHHH
19Q2A_HAEIN   H13     * E2 *          EEEEE                    HHHH
19Q2A_SF      H14     * E2 *          EEEEE                    HHHH

HMG1_HUMAN    H1      * E2 *          EEEEE                    HHHH
175  ....PYEKKV..SAPKVAE VTKKPSMGCY.EEISLQDITIGVDTLQIKKDMISAVQOYVF...L.AAVAVICEDVYG
HMG1_MOUSE    H2      * E2 *          EEEEE                    HHHH
175  ....PYEKKV..SAPKVAE VTKKPSMGCY.EEISLQDITIGVDTLQIKKDMISAVQOYVF...L.AAVAVICEDVYG
HMG1_CHICK     H3      * E2 *          EEEEE                    HHHH
142  ....PYEKNY..SAPKVAE VTKKPSMGCY.EEISLQDITIGVDTLQIKKDMISAVQOYVF...L.AAVAVICEDVYG
HMG1_PSENV     H4      * E2 *          EEEEE                    HHHH
146  ....PYEKNY..SAPKVAE VTKKPSMGCY.EEISLQDITIGVDTLQIKKDMISAVQOYVF...L.AAVAVICEDVYG
LEU1_LACLA    H5      * E2 *          EEEEE                    HHHH
140  ....EDATRT..EENPLLEAVQVADAGAT YENLIDITVGVTHDEEKGKLFKFLDNTKSDRE LIFSPLCHDDLC
N1FV_RHOCA    H6      * E2 *          EEEEE                    HHHH
139  ....EDASRT..EDDFLLAEVAAAGAI RFELIDITLIDLGAPFLAELSARIS...LLETMHANDDFG
PYCB_METUA    H7      * E2 *          EEEEE                    HHHH
144  ....TSPVYH..TIDQVLEAKLEEMCD.SEITDMLGIDIFEGEYELKELKEEIS...LFDVYHSCTSQ
H1S4_MYCTU    H8      * E2 *          EEEEE                    HHHH
133  DEHR.LKRWGTDDG DLMDVLELDESSGSRFVLDIPCKQLGGENLLEKMMAY...DQTVASGGVSSL
H1S4_STRCO    H9      * E2 *          EEEEE                    HHHH
74  CGNIKVAIKR   ..LQNEKSI VTPYVKIKLIDIMSESEELQSVIHTUSVSPKVVVPOMADHSDVILKQK...F
H1S4_HAEIN    H10     * E2 *          EEEEE                    HHHH
116  SQKIIVAISG    EEESSLLTLEDITVGVGLCCVLSKGLQLQSHDIFSFKKLIATA...E.VAVLAAGGISSE
19Q2A_HAEIN   H11     * E2 *          EEEEE                    HHHH
132  ....EAPKGLAEERKIDPVSLLKRLKVEGLREAVHTLIPKQKIQSHDIFSFKKLIATA...E.VAVLAAGGISSE
19Q2A_SF      H12     * E2 *          EEEEE                    HHHH

HMG1_HUMAN    H1      * E2 *          EEEEE                    HHHH
240  CALANILVALON SVVVDSSVSLQCCFVAKQASGNLAEDLVVHLEQ 287
HMG1_MOUSE    H2      * E2 *          EEEEE                    HHHH
240  CALANILVALON SVVVDSSVSLQCCFVAKQASGNLAEDLVVHLEQ 287
HMG1_RAT       H3      * E2 *          EEEEE                    HHHH
213  CALANILVALON SVVVDSSVSLQCCFVAKQASGNLAEDLVVHLEQ 287
HMG1_CHICK     H4      * E2 *          EEEEE                    HHHH
211  MAFANVHALAC  VRTFSSVSLQCCFVAKQASGNVAEDLILHLEQ 258
HMG1_PSENV     H5      * E2 *          EEEEE                    HHHH
208  MAFANVHALAC  VRTFSSVSLQCCFVAKQASGNVAEDLILHLEQ 258
LEU1_LACLA    H6      * E2 *          EEEEE                    HHHH
206  MAFANVHALAC  VRTFSSVSLQCCFVAKQASGNVAEDLILHLEQ 258
PYCB_METUA    H7      * E2 *          EEEEE                    HHHH
206  LAPMVIKYLIEA EALMIVCAIQEPA...METSOPPLSLVVALKE 249
H1S4_MYCTU    H8      * E2 *          EEEEE                    HHHH
200  DEERATATLTHS QVEGALVKA...LYASRPTLPQALAAV 236
H1S4_STRCO    H9      * E2 *          EEEEE                    HHHH
208  DD..LALAGLPPA...VEGALVKA...LYASRPTLPQALAAV 236
H1S4_ECOLI    H10     * E2 *          EEEEE                    HHHH
210  AD...EALKGT...RCVTVFA...LLEGKPTVKEA.FACV 241
H1S4_HAEIN    H11     * E2 *          EEEEE                    HHHH
200  NSHITKQKHETINGLINQVLENVFA.....FLGGILTVYVKRYAR 240
19Q2A_HAEIN   H12     * E2 *          EEEEE                    HHHH
19Q2A_SF      H13     * E2 *          EEEEE                    HHHH

```

Figure 3




Figure 4




Figure 5

Structural (ab)8 TIM barrel model of 3-hydroxy-3-methylglutaryl coenzyme A lyase. Mutation of Ser75, Ser201 and Asp204 impairs the catalytic activity

Núria Casals, Paulino Gómez-Puertas, Juan Pié, Cecília Mir, Ramón Roca, Beatriz Puisac, Rosa Aledo, Josep Clotet, Sebastián Menao, Dolors Serra, Guillermina Asins, Jacqueline Till, Alun C. Elias-Jones, Juan C Cresto, Nestor A. Chamoles, José E. Abdenur, Ertan Mayatepek, Guy Besley, Alfonso Valencia and Fausto G. Hegardt

J. Biol. Chem. published online May 13, 2003

Access the most updated version of this article at doi: [10.1074/jbc.M304276200](https://doi.org/10.1074/jbc.M304276200)

Alerts:

- [When this article is cited](#)
- [When a correction for this article is posted](#)

[Click here](#) to choose from all of JBC's e-mail alerts